HANDBOOK OF GENERAL MEDICINE VOL 1:@0.076190:0.972666:0.349932:0.972666:0.349932:0.958637:0.076190:0.958637:0.009179:0.009945:0.009945:0.009999:0.007714:0.011679:0.011679:0.007943:0.003723:0.011679:0.006518:0.003723:0.011719:0.007203:0.009945:0.007203:0.008158:0.009945:0.006209:0.003723:0.012351:0.007203:0.009999:0.003037:0.010926:0.003037:0.009945:0.007203:0.003723:0.009434:0.011679:0.006209:0.003723:0.007445
218:@0.078769:0.033217:0.109813:0.033217:0.109813:0.013052:0.078769:0.013052:0.010348:0.010348:0.010348
TREATMENT AppROACHEs:@0.397030:0.032906:0.624375:0.032906:0.624375:0.013617:0.397030:0.013617:0.007872:0.011217:0.009905:0.013674:0.007872:0.016982:0.009905:0.013674:0.007872:0.005119:0.013674:0.010939:0.010939:0.011217:0.016058:0.013674:0.015023:0.012621:0.009905:0.009202
The infusion is given over two hours and the patient is :@0.076190:0.084931:0.485145:0.084931:0.485145:0.069149:0.076190:0.069149:0.006441:0.009223:0.009827:0.006063:0.003024:0.009223:0.004747:0.009192:0.005866:0.003024:0.009903:0.009223:0.006063:0.003024:0.005866:0.006078:0.010175:0.003024:0.008376:0.009827:0.009223:0.006063:0.009903:0.008376:0.009827:0.004551:0.006063:0.005125:0.012564:0.009903:0.006063:0.009223:0.009903:0.009192:0.004551:0.005866:0.006063:0.010326:0.009223:0.010357:0.006063:0.005125:0.009223:0.009827:0.006063:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.006063:0.003024:0.005866:0.004188
observed  for  an  hour.  Infliximab  is  contra-indicated  in :@0.076190:0.099259:0.485130:0.099259:0.485130:0.083477:0.076190:0.083477:0.009903:0.010311:0.005866:0.009827:0.004551:0.008376:0.009827:0.010357:0.004188:0.002343:0.004747:0.009903:0.004551:0.004188:0.002343:0.010326:0.009223:0.004188:0.002343:0.009223:0.009903:0.009192:0.004551:0.004188:0.004188:0.002328:0.003417:0.009223:0.003666:0.003666:0.003024:0.007257:0.003024:0.014182:0.010326:0.010311:0.004188:0.002343:0.003024:0.005866:0.004188:0.002359:0.009782:0.009903:0.009223:0.005125:0.004551:0.010326:0.005020:0.003024:0.009223:0.010357:0.003024:0.009782:0.010326:0.005125:0.009827:0.010357:0.004188:0.002343:0.003024:0.009223:0.004188
the presence of active infections, such as tuberculosis, :@0.076190:0.113587:0.485145:0.113587:0.485145:0.097804:0.076190:0.097804:0.005125:0.009223:0.009827:0.005171:0.010311:0.004551:0.009827:0.005866:0.009827:0.009223:0.009782:0.009827:0.005171:0.009903:0.004747:0.005171:0.010326:0.009782:0.005125:0.003024:0.008376:0.009827:0.005186:0.003024:0.009223:0.004747:0.009827:0.009782:0.005125:0.003024:0.009903:0.009223:0.005866:0.004188:0.005171:0.005866:0.009192:0.009782:0.009223:0.005171:0.010326:0.005866:0.005186:0.005125:0.009192:0.010311:0.009827:0.004551:0.009782:0.009192:0.003024:0.009903:0.005866:0.003024:0.005866:0.004188:0.004188
chronic hepatitis B, heart failure, hypersensitivity to inflixi:@0.076190:0.127915:0.475938:0.127915:0.475938:0.112132:0.076190:0.112132:0.009782:0.009223:0.004551:0.009903:0.009223:0.003024:0.009782:0.003583:0.009223:0.009827:0.010311:0.010326:0.005125:0.003024:0.005125:0.003024:0.005866:0.003583:0.008678:0.004188:0.003583:0.009223:0.009827:0.010326:0.004551:0.005125:0.003583:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.004188:0.003583:0.009223:0.008104:0.010311:0.009827:0.004551:0.005866:0.009827:0.009223:0.005866:0.003024:0.005125:0.003024:0.008376:0.003024:0.005125:0.008104:0.003598:0.005125:0.009903:0.003583:0.003024:0.009223:0.003666:0.003666:0.003024:0.007257:0.003024
-:@0.475938:0.127915:0.480957:0.127915:0.480957:0.112132:0.475938:0.112132:0.005020
mab and pregnancy. The side effects include infusion-:@0.076190:0.142243:0.480957:0.142243:0.480957:0.126460:0.076190:0.126460:0.014182:0.010326:0.010311:0.005171:0.010326:0.009223:0.010357:0.005171:0.010311:0.004551:0.009827:0.010175:0.009223:0.010326:0.009223:0.009782:0.008104:0.004188:0.005171:0.006441:0.009223:0.009827:0.005171:0.005866:0.003024:0.010357:0.009827:0.005171:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.005866:0.005171:0.003024:0.009223:0.009782:0.003024:0.009192:0.010357:0.009827:0.005171:0.003024:0.009223:0.004747:0.009192:0.005866:0.003024:0.009903:0.009223:0.005020
site reactions, headache, fever, infections, allergic re-:@0.076190:0.156571:0.480972:0.156571:0.480972:0.140788:0.076190:0.140788:0.005866:0.003024:0.005125:0.009827:0.006244:0.004551:0.009827:0.010326:0.009782:0.005125:0.003024:0.009903:0.009223:0.005866:0.004188:0.006244:0.009223:0.009827:0.010326:0.010357:0.010326:0.009782:0.009223:0.009827:0.004188:0.006244:0.004747:0.009827:0.008376:0.009827:0.004551:0.004188:0.006244:0.003024:0.009223:0.004747:0.009827:0.009782:0.005125:0.003024:0.009903:0.009223:0.005866:0.004188:0.006244:0.010326:0.003024:0.003024:0.009827:0.004551:0.010175:0.003024:0.009782:0.006244:0.004551:0.009827:0.005020
actions and raised liver enzymes.:@0.076190:0.170899:0.316492:0.170899:0.316492:0.155116:0.076190:0.155116:0.010326:0.009782:0.005125:0.003024:0.009903:0.009223:0.005866:0.004188:0.010326:0.009223:0.010357:0.004188:0.004551:0.010326:0.003024:0.005866:0.009827:0.010357:0.004188:0.003024:0.003024:0.008376:0.009827:0.004551:0.004188:0.009827:0.009223:0.006426:0.008104:0.014182:0.009827:0.005866:0.004188
Adalimumab :@0.076190:0.200617:0.176278:0.200617:0.176278:0.184118:0.076190:0.184118:0.011188:0.009979:0.009979:0.003629:0.003629:0.014212:0.009071:0.014212:0.009979:0.009979:0.004233
This is a recombinant human immunoglobulin G 1 (IgG1) :@0.076190:0.217508:0.485115:0.217508:0.485115:0.201725:0.076190:0.201725:0.006441:0.009223:0.003024:0.005866:0.003492:0.003024:0.005866:0.003492:0.010326:0.003492:0.004551:0.009827:0.009782:0.009903:0.014182:0.010311:0.003024:0.009223:0.010326:0.009223:0.005125:0.003477:0.009223:0.009192:0.014182:0.010326:0.009223:0.003477:0.003024:0.014182:0.014182:0.009192:0.009223:0.009903:0.010175:0.003024:0.009903:0.010311:0.009192:0.003024:0.003024:0.009223:0.003477:0.013184:0.003492:0.008376:0.003492:0.005579:0.003417:0.010175:0.013184:0.008376:0.005579:0.004188
monoclonal antibody-binding, soluble and membrane-:@0.076190:0.231836:0.480957:0.231836:0.480957:0.216053:0.076190:0.216053:0.014182:0.009903:0.009223:0.009903:0.009782:0.003024:0.009903:0.009223:0.010326:0.003024:0.004203:0.010326:0.009223:0.005125:0.003024:0.010311:0.009903:0.010357:0.008104:0.005020:0.010311:0.003024:0.009223:0.010357:0.003024:0.009223:0.010175:0.004188:0.004218:0.005866:0.009903:0.003024:0.009192:0.010311:0.003024:0.009827:0.004218:0.010326:0.009223:0.010357:0.004218:0.014182:0.009827:0.014182:0.010311:0.004551:0.010326:0.009223:0.009827:0.005020
bound  TNF-alpha.  The  indication is for  moderate  to :@0.076190:0.246163:0.485145:0.246163:0.485145:0.230381:0.076190:0.230381:0.010311:0.009903:0.009192:0.009223:0.010357:0.004188:0.004762:0.006441:0.011188:0.007333:0.005020:0.010326:0.003024:0.010311:0.009223:0.010326:0.004188:0.004188:0.004762:0.006441:0.009223:0.009827:0.004188:0.004762:0.003024:0.009223:0.010357:0.003024:0.009782:0.010326:0.005125:0.003024:0.009903:0.009223:0.008966:0.003024:0.005866:0.008966:0.004747:0.009903:0.004551:0.004188:0.004762:0.014182:0.009903:0.010357:0.009827:0.004551:0.010326:0.005125:0.009827:0.004188:0.004762:0.005125:0.009903:0.004188
severe psoriasis, failure of conventional systemic treat-:@0.076190:0.260491:0.480957:0.260491:0.480957:0.244709:0.076190:0.244709:0.005866:0.009827:0.008376:0.009827:0.004551:0.009827:0.005912:0.010311:0.005866:0.009903:0.004551:0.003024:0.010326:0.005866:0.003024:0.005881:0.004188:0.005912:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.005912:0.009903:0.004747:0.005912:0.009782:0.009903:0.009223:0.008376:0.009827:0.009223:0.005125:0.003024:0.009903:0.009223:0.010326:0.003024:0.005912:0.005866:0.008104:0.005866:0.005125:0.009827:0.014182:0.003024:0.009782:0.005927:0.005125:0.004551:0.009827:0.010326:0.005140:0.005020
ment,  phototherapy and psoriatic arthritis.  Dosage is :@0.076190:0.274819:0.485130:0.274819:0.485130:0.259037:0.076190:0.259037:0.014182:0.009827:0.009223:0.005125:0.004188:0.004188:0.003674:0.010311:0.009223:0.009903:0.005125:0.009903:0.005125:0.009207:0.009827:0.004551:0.010326:0.010311:0.008104:0.007877:0.010326:0.009223:0.010357:0.007877:0.010311:0.005866:0.009903:0.004551:0.003024:0.010326:0.005125:0.003024:0.009782:0.007877:0.010326:0.004551:0.005125:0.009223:0.004551:0.003024:0.005125:0.003024:0.005866:0.004188:0.004188:0.003674:0.011249:0.009903:0.005866:0.010326:0.010175:0.009827:0.007877:0.003024:0.005866:0.004188
80 mg subcutaneous on day 0 for induction, followed :@0.076190:0.289147:0.485115:0.289147:0.485115:0.273365:0.076190:0.273365:0.008376:0.008376:0.006002:0.014182:0.010175:0.005987:0.005866:0.009192:0.010311:0.009782:0.009192:0.005125:0.010326:0.009223:0.009827:0.009903:0.009192:0.005866:0.005987:0.009903:0.009223:0.005987:0.010357:0.010326:0.008104:0.006002:0.008376:0.006002:0.004747:0.009903:0.004551:0.005987:0.003024:0.009223:0.010357:0.009192:0.009782:0.005125:0.003024:0.009903:0.009223:0.004188:0.005987:0.004747:0.009903:0.003024:0.003024:0.009903:0.012564:0.009827:0.010357:0.004188
by 40 mg every two weeks for maintenance. It is contra-:@0.076190:0.303475:0.480957:0.303475:0.480957:0.287692:0.076190:0.287692:0.010311:0.008104:0.003644:0.008376:0.008376:0.003644:0.014182:0.010175:0.003644:0.009827:0.008376:0.009827:0.004551:0.008104:0.003644:0.005125:0.012564:0.009903:0.003644:0.012564:0.009827:0.009827:0.007590:0.005866:0.003644:0.004747:0.009903:0.004551:0.003644:0.014182:0.010326:0.003024:0.009223:0.005125:0.009827:0.009223:0.010326:0.009223:0.009782:0.009827:0.004188:0.003644:0.003417:0.005125:0.003644:0.003024:0.005866:0.003659:0.009782:0.009903:0.009223:0.005125:0.004551:0.010326:0.005020
indicated in active infections, including tuberculosis, :@0.076190:0.317803:0.485160:0.317803:0.485160:0.302020:0.076190:0.302020:0.003024:0.009223:0.010357:0.003024:0.009782:0.010326:0.005125:0.009827:0.010357:0.008845:0.003024:0.009223:0.008845:0.010326:0.009782:0.005125:0.003024:0.008376:0.009827:0.008845:0.003024:0.009223:0.004747:0.009827:0.009782:0.005125:0.003024:0.009903:0.009223:0.005866:0.004188:0.008845:0.003024:0.009223:0.009782:0.003024:0.009192:0.010357:0.003024:0.009223:0.010175:0.008845:0.005125:0.009192:0.010311:0.009827:0.004551:0.009782:0.009192:0.003024:0.009903:0.005866:0.003024:0.005866:0.004188:0.004188
congestive  cardiac  failure,  pregnancy  and  allergy to :@0.076190:0.332131:0.485130:0.332131:0.485130:0.316348:0.076190:0.316348:0.009782:0.009903:0.009223:0.010175:0.009827:0.005866:0.005125:0.003024:0.008376:0.009827:0.004188:0.002661:0.009782:0.010326:0.004551:0.010357:0.003024:0.010326:0.009782:0.004188:0.002661:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.004188:0.004188:0.002661:0.010311:0.004551:0.009827:0.010175:0.009223:0.010326:0.009223:0.009782:0.008104:0.004188:0.002661:0.010326:0.009223:0.010357:0.004188:0.002661:0.010326:0.003024:0.003024:0.009827:0.004551:0.010175:0.008104:0.006864:0.005125:0.009903:0.004188
adalimumab. The side effects include injection-site re-:@0.076190:0.346459:0.480957:0.346459:0.480957:0.330676:0.076190:0.330676:0.010326:0.010357:0.010326:0.003024:0.003024:0.014182:0.009192:0.014182:0.010326:0.010311:0.004188:0.006002:0.006441:0.009223:0.009827:0.005987:0.005866:0.003024:0.010357:0.009827:0.006002:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.005866:0.005987:0.003024:0.009223:0.009782:0.003024:0.009192:0.010357:0.009827:0.005987:0.003024:0.009223:0.003069:0.009827:0.009782:0.005125:0.003024:0.009903:0.009223:0.005020:0.005866:0.003024:0.005125:0.009827:0.005987:0.004551:0.009827:0.005020
action, infections and headache. :@0.076190:0.360787:0.327242:0.360787:0.327242:0.345004:0.076190:0.345004:0.010326:0.009782:0.005125:0.003024:0.009903:0.009223:0.004188:0.004188:0.003024:0.009223:0.004747:0.009827:0.009782:0.005125:0.003024:0.009903:0.009223:0.005866:0.004188:0.010326:0.009223:0.010357:0.004188:0.009223:0.009827:0.010326:0.010357:0.010326:0.009782:0.009223:0.009827:0.004188:0.004188
IL-12/IL-23p40 inhibitor:@0.076190:0.390505:0.240685:0.390505:0.240685:0.374006:0.076190:0.374006:0.004233:0.006652:0.006350:0.008467:0.008467:0.006955:0.004233:0.006652:0.006350:0.008467:0.008467:0.009979:0.008467:0.008467:0.004233:0.003629:0.009071:0.009071:0.003629:0.009979:0.003629:0.004536:0.009676:0.004838
ustekinumab :@0.076190:0.415096:0.175674:0.415096:0.175674:0.398598:0.076190:0.398598:0.009676:0.006652:0.004536:0.009676:0.008769:0.003629:0.009071:0.009071:0.014212:0.009979:0.009979:0.004233
This is a recombinant, human IgG1 antibody with high :@0.076190:0.431987:0.485130:0.431987:0.485130:0.416205:0.076190:0.416205:0.006441:0.009223:0.003024:0.005866:0.005760:0.003024:0.005866:0.005760:0.010326:0.005760:0.004551:0.009827:0.009782:0.009903:0.014182:0.010311:0.003024:0.009223:0.010326:0.009223:0.005125:0.004188:0.005745:0.009223:0.009192:0.014182:0.010326:0.009223:0.005760:0.003417:0.010175:0.013184:0.008376:0.005760:0.010326:0.009223:0.005125:0.003024:0.010311:0.009903:0.010357:0.008104:0.005760:0.012564:0.003024:0.005125:0.009223:0.005760:0.009223:0.003024:0.010175:0.009223:0.004188
specificity  and  affinity  to  the  p40  subunit  of  IL-12  and :@0.076190:0.446315:0.485115:0.446315:0.485115:0.430533:0.076190:0.430533:0.005866:0.010311:0.009827:0.009782:0.003024:0.003681:0.003681:0.009782:0.003024:0.005125:0.008104:0.004188:0.002464:0.010326:0.009223:0.010357:0.004188:0.002449:0.010326:0.004747:0.003681:0.003681:0.009223:0.003024:0.005125:0.008104:0.004188:0.002449:0.005125:0.009903:0.004188:0.002449:0.005125:0.009223:0.009827:0.004188:0.002449:0.010311:0.008376:0.008376:0.004188:0.002464:0.005866:0.009192:0.010311:0.009192:0.009223:0.003024:0.005125:0.004188:0.002449:0.009903:0.004747:0.004188:0.002449:0.003417:0.006985:0.005020:0.008376:0.008376:0.004188:0.002464:0.010326:0.009223:0.010357:0.004188
IL-23. The indications are as for the other biologics, but :@0.076190:0.460643:0.485130:0.460643:0.485130:0.444861:0.076190:0.444861:0.003417:0.006985:0.005020:0.008376:0.008376:0.004188:0.005261:0.006441:0.009223:0.009827:0.005261:0.003024:0.009223:0.010357:0.003024:0.009782:0.010326:0.005125:0.003024:0.009903:0.009223:0.005866:0.005261:0.010326:0.004551:0.009827:0.005246:0.010326:0.005866:0.005261:0.004747:0.009903:0.004551:0.005246:0.005125:0.009223:0.009827:0.005246:0.009903:0.005125:0.009223:0.009827:0.004551:0.005246:0.010311:0.003024:0.009903:0.003024:0.009903:0.010175:0.003024:0.009782:0.005866:0.004188:0.005261:0.010311:0.009192:0.005125:0.004188
it is also used for psoriatic arthritis. Dosage is 45/90 mg :@0.076190:0.474971:0.485145:0.474971:0.485145:0.459189:0.076190:0.459189:0.003024:0.005125:0.005655:0.003024:0.005866:0.005655:0.010326:0.003024:0.005866:0.009903:0.005655:0.009192:0.005866:0.009827:0.010357:0.005655:0.004747:0.009903:0.004551:0.005639:0.010311:0.005866:0.009903:0.004551:0.003024:0.010326:0.005125:0.003024:0.009782:0.005655:0.010326:0.004551:0.005125:0.009223:0.004551:0.003024:0.005125:0.003024:0.005866:0.004188:0.005655:0.011249:0.009903:0.005866:0.010326:0.010175:0.009827:0.005655:0.003024:0.005866:0.005655:0.008376:0.008376:0.006607:0.008376:0.008376:0.005670:0.014182:0.010175:0.004188
subcutaneously at weeks 0 and 4 for  induction.  The :@0.076190:0.489299:0.485145:0.489299:0.485145:0.473516:0.076190:0.473516:0.005866:0.009192:0.010311:0.009782:0.009192:0.005125:0.010326:0.009223:0.009827:0.009903:0.009192:0.005866:0.003024:0.008104:0.008043:0.010326:0.005125:0.008043:0.012564:0.009827:0.009827:0.007590:0.005866:0.008043:0.008376:0.008043:0.010326:0.009223:0.010357:0.008043:0.008376:0.008043:0.004747:0.009903:0.004551:0.004188:0.003840:0.003024:0.009223:0.010357:0.009192:0.009782:0.005125:0.003024:0.009903:0.009223:0.004188:0.004188:0.003840:0.006441:0.009223:0.009827:0.004188
45 mg is intended for patients weighing <100 kg and the :@0.076190:0.503627:0.485145:0.503627:0.485145:0.487844:0.076190:0.487844:0.008376:0.008376:0.003644:0.014182:0.010175:0.003644:0.003024:0.005866:0.003644:0.003024:0.009223:0.005125:0.009827:0.009223:0.010357:0.009827:0.010357:0.003644:0.004747:0.009903:0.004551:0.003629:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.003644:0.012564:0.009827:0.003024:0.010175:0.009223:0.003024:0.009223:0.010175:0.003644:0.009162:0.008376:0.008376:0.008376:0.003629:0.007590:0.010175:0.003644:0.010326:0.009223:0.010357:0.003644:0.005125:0.009223:0.009827:0.004188
90 mg for patients weighing 100 kg or more. The main-:@0.076175:0.517955:0.480942:0.517955:0.480942:0.502172:0.076175:0.502172:0.008376:0.008376:0.005125:0.014182:0.010175:0.005110:0.004747:0.009903:0.004551:0.005110:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.005110:0.012564:0.009827:0.003024:0.010175:0.009223:0.003024:0.009223:0.010175:0.005110:0.008376:0.008376:0.008376:0.005125:0.007590:0.010175:0.005110:0.009903:0.004551:0.005110:0.014182:0.009903:0.004551:0.009827:0.004188:0.005110:0.006441:0.009223:0.009827:0.005110:0.014182:0.010326:0.003024:0.009223:0.005020
tenance treatment is 45/90 mg s.c. every 12 weeks. It is :@0.076175:0.532283:0.485115:0.532283:0.485115:0.516500:0.076175:0.516500:0.005125:0.009827:0.009223:0.010326:0.009223:0.009782:0.009827:0.004596:0.005125:0.004551:0.009827:0.010326:0.005125:0.014167:0.009827:0.009223:0.005125:0.004596:0.003024:0.005866:0.004611:0.008376:0.008376:0.006607:0.008376:0.008376:0.004611:0.014182:0.010175:0.004596:0.005866:0.004188:0.009782:0.004188:0.004596:0.009827:0.008376:0.009827:0.004551:0.008104:0.004596:0.008376:0.008376:0.004611:0.012564:0.009827:0.009827:0.007590:0.005866:0.004188:0.004596:0.003417:0.005125:0.004596:0.003024:0.005866:0.004188
contra-indicated in active infections, including tubercu-:@0.076175:0.546611:0.480942:0.546611:0.480942:0.530828:0.076175:0.530828:0.009782:0.009903:0.009223:0.005125:0.004551:0.010326:0.005020:0.003024:0.009223:0.010357:0.003024:0.009782:0.010326:0.005125:0.009827:0.010357:0.003417:0.003024:0.009223:0.003432:0.010326:0.009782:0.005125:0.003024:0.008376:0.009827:0.003432:0.003024:0.009223:0.004747:0.009827:0.009782:0.005125:0.003024:0.009903:0.009223:0.005866:0.004188:0.003417:0.003024:0.009223:0.009782:0.003024:0.009192:0.010357:0.003024:0.009223:0.010175:0.003432:0.005125:0.009192:0.010311:0.009827:0.004551:0.009782:0.009192:0.005020
losis, pregnancy, hypersensitivity and malignancy. The :@0.076175:0.560939:0.485130:0.560939:0.485130:0.545156:0.076175:0.545156:0.003024:0.009903:0.005866:0.003024:0.005866:0.004188:0.006320:0.010311:0.004551:0.009827:0.010175:0.009223:0.010326:0.009223:0.009782:0.008104:0.004188:0.006320:0.009223:0.008104:0.010311:0.009827:0.004551:0.005866:0.009827:0.009223:0.005866:0.003024:0.005125:0.003024:0.008376:0.003024:0.005125:0.008104:0.006335:0.010326:0.009223:0.010357:0.006320:0.014182:0.010326:0.003024:0.003024:0.010175:0.009223:0.010326:0.009223:0.009782:0.008104:0.004188:0.006320:0.006441:0.009223:0.009827:0.004188
side effects include upper respiratory tract infections, :@0.076175:0.575266:0.485145:0.575266:0.485145:0.559484:0.076175:0.559484:0.005866:0.003024:0.010357:0.009827:0.007030:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.005866:0.007030:0.003024:0.009223:0.009782:0.003024:0.009192:0.010357:0.009827:0.007030:0.009192:0.010311:0.010311:0.009827:0.004551:0.007030:0.004551:0.009827:0.005866:0.010311:0.003024:0.004551:0.010326:0.005125:0.009903:0.004551:0.008104:0.007030:0.005125:0.004551:0.010326:0.009782:0.005125:0.007030:0.003024:0.009223:0.004747:0.009827:0.009782:0.005125:0.003024:0.009903:0.009223:0.005866:0.004188:0.004188
pain and reactions at the injection site, headache, sore :@0.076175:0.589594:0.485130:0.589594:0.485130:0.573812:0.076175:0.573812:0.010311:0.010326:0.003024:0.009223:0.003916:0.010326:0.009223:0.010357:0.003916:0.004551:0.009827:0.010326:0.009782:0.005125:0.003024:0.009903:0.009223:0.005866:0.003901:0.010326:0.005125:0.003916:0.005125:0.009223:0.009827:0.003901:0.003024:0.009223:0.003069:0.009827:0.009782:0.005125:0.003024:0.009903:0.009223:0.003901:0.005866:0.003024:0.005125:0.009827:0.004188:0.003916:0.009223:0.009827:0.010326:0.010357:0.010326:0.009782:0.009223:0.009827:0.004188:0.003901:0.005866:0.009903:0.004551:0.009827:0.004188
throat and allergic reactions.:@0.076175:0.603922:0.288447:0.603922:0.288447:0.588140:0.076175:0.588140:0.005125:0.009223:0.004551:0.009903:0.010326:0.005125:0.004188:0.010326:0.009223:0.010357:0.004188:0.010326:0.003024:0.003024:0.009827:0.004551:0.010175:0.003024:0.009782:0.004188:0.004551:0.009827:0.010326:0.009782:0.005125:0.003024:0.009903:0.009223:0.005866:0.004188
il-17 targeted therapy:@0.076175:0.633640:0.238856:0.633640:0.238856:0.617142:0.076175:0.617142:0.004233:0.006652:0.006350:0.008467:0.008467:0.004233:0.004536:0.009979:0.004838:0.009979:0.009676:0.004536:0.009676:0.009979:0.004233:0.004536:0.009071:0.009676:0.004838:0.009979:0.009979:0.008769
secukinumab:@0.076175:0.658232:0.177170:0.658232:0.177170:0.641734:0.076175:0.641734:0.007862:0.009676:0.009676:0.009071:0.008769:0.003629:0.009071:0.009071:0.014212:0.009979:0.009979
This is a fully human  monoclonal IgG1 antibody that :@0.076175:0.675123:0.485115:0.675123:0.485115:0.659340:0.076175:0.659340:0.006441:0.009223:0.003024:0.005866:0.007620:0.003024:0.005866:0.007620:0.010326:0.007620:0.004747:0.009192:0.003024:0.003024:0.008104:0.007620:0.009223:0.009192:0.014182:0.010326:0.009223:0.004188:0.003417:0.014182:0.009903:0.009223:0.009903:0.009767:0.003024:0.009903:0.009223:0.010326:0.003024:0.007620:0.003417:0.010175:0.013184:0.008376:0.007620:0.010326:0.009223:0.005125:0.003024:0.010311:0.009903:0.010357:0.008104:0.007620:0.005125:0.009223:0.010326:0.005125:0.004188
binds and antagonises the cytokine IL-17A. Indications :@0.076175:0.689451:0.485115:0.689451:0.485115:0.673668:0.076175:0.673668:0.010311:0.003024:0.009223:0.010357:0.005866:0.005609:0.010326:0.009223:0.010357:0.005594:0.010326:0.009223:0.005125:0.010326:0.010175:0.009903:0.009223:0.003024:0.005866:0.009827:0.005866:0.005609:0.005125:0.009223:0.009827:0.005594:0.009782:0.008104:0.005125:0.009903:0.007590:0.003024:0.009223:0.009827:0.005594:0.003417:0.006985:0.005020:0.008376:0.008376:0.011188:0.004188:0.005609:0.003417:0.009223:0.010357:0.003024:0.009782:0.010326:0.005125:0.003024:0.009903:0.009223:0.005866:0.004188
are for moderate to severe psoriasis which has not re-:@0.076175:0.703779:0.480957:0.703779:0.480957:0.687996:0.076175:0.687996:0.010326:0.004551:0.009827:0.005760:0.004747:0.009903:0.004551:0.005760:0.014182:0.009903:0.010357:0.009827:0.004551:0.010326:0.005125:0.009827:0.005760:0.005125:0.009903:0.005760:0.005866:0.009827:0.008376:0.009827:0.004551:0.009827:0.005760:0.010311:0.005866:0.009903:0.004551:0.003024:0.010326:0.005866:0.003024:0.005866:0.005775:0.012564:0.009223:0.003024:0.009782:0.009223:0.005760:0.009223:0.010326:0.005866:0.005760:0.009223:0.009903:0.005125:0.005760:0.004551:0.009827:0.005020
sponded to conventional systemic therapy. Dosage is :@0.076175:0.718107:0.485115:0.718107:0.485115:0.702324:0.076175:0.702324:0.005866:0.010311:0.009903:0.009223:0.010357:0.009827:0.010357:0.006214:0.005125:0.009903:0.006199:0.009782:0.009903:0.009223:0.008376:0.009827:0.009223:0.005125:0.003024:0.009903:0.009223:0.010326:0.003024:0.006214:0.005866:0.008104:0.005866:0.005125:0.009827:0.014182:0.003024:0.009782:0.006214:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.004188:0.006199:0.011249:0.009903:0.005866:0.010326:0.010175:0.009827:0.006214:0.003024:0.005866:0.004188
300 mg subcutaneously at weeks 0, 1, 2, 3, for induction. :@0.076175:0.732435:0.485130:0.732435:0.485130:0.716652:0.076175:0.716652:0.008376:0.008376:0.008376:0.003674:0.014182:0.010175:0.003674:0.005866:0.009192:0.010311:0.009782:0.009192:0.005125:0.010326:0.009223:0.009827:0.009903:0.009192:0.005866:0.003024:0.008104:0.003674:0.010326:0.005125:0.003674:0.012564:0.009827:0.009827:0.007590:0.005866:0.003674:0.008376:0.004188:0.003674:0.008376:0.004188:0.003674:0.008376:0.004188:0.003674:0.008376:0.004188:0.003674:0.004747:0.009903:0.004551:0.003659:0.003024:0.009223:0.010357:0.009192:0.009782:0.005125:0.003024:0.009903:0.009223:0.004188:0.004188
This is followed by 300 mg s.c. every four weeks for main-:@0.076175:0.746763:0.480912:0.746763:0.480912:0.730980:0.076175:0.730980:0.006441:0.009223:0.003024:0.005866:0.003659:0.003024:0.005866:0.003674:0.004747:0.009903:0.003024:0.003024:0.009903:0.012564:0.009827:0.010357:0.003659:0.010311:0.008104:0.003674:0.008376:0.008376:0.008376:0.003674:0.014182:0.010175:0.003659:0.005866:0.004188:0.009782:0.004188:0.003659:0.009827:0.008376:0.009827:0.004551:0.008104:0.003659:0.004747:0.009903:0.009192:0.004551:0.003659:0.012564:0.009827:0.009827:0.007590:0.005866:0.003659:0.004747:0.009903:0.004551:0.003659:0.014182:0.010326:0.003024:0.009223:0.005020
tenance,  starting in week four. The contra-indications :@0.076175:0.761090:0.485130:0.761090:0.485130:0.745308:0.076175:0.745308:0.005125:0.009827:0.009223:0.010326:0.009223:0.009782:0.009827:0.004188:0.004188:0.002616:0.005866:0.005125:0.010326:0.004551:0.005125:0.003024:0.009223:0.010175:0.006819:0.003024:0.009223:0.006819:0.012564:0.009827:0.009827:0.007590:0.006819:0.004747:0.009903:0.009192:0.004551:0.004188:0.006819:0.006441:0.009223:0.009827:0.006819:0.009782:0.009903:0.009223:0.005125:0.004551:0.010326:0.005020:0.003024:0.009223:0.010357:0.003024:0.009782:0.010326:0.005125:0.003024:0.009903:0.009223:0.005866:0.004188
are acute infections, including tuberculosis, pregnancy, :@0.076175:0.775418:0.485115:0.775418:0.485115:0.759636:0.076175:0.759636:0.010326:0.004551:0.009827:0.003855:0.010326:0.009782:0.009192:0.005125:0.009827:0.003855:0.003024:0.009223:0.004747:0.009827:0.009782:0.005125:0.003024:0.009903:0.009223:0.005866:0.004188:0.003855:0.003024:0.009223:0.009782:0.003024:0.009192:0.010357:0.003024:0.009223:0.010175:0.003855:0.005125:0.009192:0.010311:0.009827:0.004551:0.009782:0.009192:0.003024:0.009903:0.005866:0.003024:0.005866:0.004188:0.003855:0.010311:0.004551:0.009827:0.010175:0.009223:0.010326:0.009223:0.009782:0.008104:0.004188:0.004188
live  attenuated viruses, hypersensitivity  reactions and :@0.076175:0.789746:0.485130:0.789746:0.485130:0.773964:0.076175:0.773964:0.003024:0.003024:0.008376:0.009827:0.004188:0.003629:0.010326:0.005125:0.005125:0.009827:0.009223:0.009192:0.010326:0.005125:0.009827:0.010357:0.007801:0.008376:0.003024:0.004551:0.009192:0.005866:0.009827:0.005866:0.004188:0.007801:0.009223:0.008104:0.010311:0.009827:0.004551:0.005866:0.009827:0.009223:0.005866:0.003024:0.005125:0.003024:0.008376:0.003024:0.005125:0.008104:0.004188:0.003629:0.004551:0.009827:0.010326:0.009782:0.005125:0.003024:0.009903:0.009223:0.005866:0.007801:0.010326:0.009223:0.010357:0.004188
cancer. The side effects are infections, diarrhoea, ele-:@0.076175:0.804074:0.480942:0.804074:0.480942:0.788292:0.076175:0.788292:0.009782:0.010326:0.009223:0.009782:0.009827:0.004551:0.004188:0.005715:0.006441:0.009223:0.009827:0.005715:0.005866:0.003024:0.010357:0.009827:0.005715:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.005866:0.005715:0.010326:0.004551:0.009827:0.005715:0.003024:0.009223:0.004747:0.009827:0.009782:0.005125:0.003024:0.009903:0.009223:0.005866:0.004188:0.005715:0.010357:0.003024:0.010326:0.004551:0.004551:0.009223:0.009903:0.009827:0.010326:0.004188:0.005700:0.009827:0.003024:0.009827:0.005020
vated liver enzymes and allergic reactions.:@0.076175:0.818402:0.388837:0.818402:0.388837:0.802619:0.076175:0.802619:0.008376:0.010326:0.005125:0.009827:0.010357:0.004188:0.003024:0.003024:0.008376:0.009827:0.004551:0.004188:0.009827:0.009223:0.006426:0.008104:0.014182:0.009827:0.005866:0.004188:0.010326:0.009223:0.010357:0.004188:0.010326:0.003024:0.003024:0.009827:0.004551:0.010175:0.003024:0.009782:0.004188:0.004551:0.009827:0.010326:0.009782:0.005125:0.003024:0.009903:0.009223:0.005866:0.004188
GuiDeline:@0.076190:0.851427:0.167845:0.851427:0.167845:0.831262:0.076190:0.831262:0.015522:0.011826:0.005174:0.012935:0.009609:0.008131:0.005174:0.013674:0.009609
The treatment algorithm for psoriasis is contained in Fig-:@0.076190:0.867532:0.480942:0.867532:0.480942:0.851749:0.076190:0.851749:0.006441:0.009223:0.009827:0.004369:0.005125:0.004551:0.009827:0.010326:0.005125:0.014182:0.009827:0.009223:0.005125:0.004369:0.010326:0.003024:0.010175:0.009903:0.004551:0.003024:0.005125:0.009223:0.014182:0.004369:0.004747:0.009903:0.004551:0.004369:0.010311:0.005866:0.009903:0.004551:0.003024:0.010326:0.005866:0.003024:0.005866:0.004385:0.003024:0.005866:0.004385:0.009782:0.009903:0.009223:0.005125:0.010326:0.003024:0.009223:0.009827:0.010357:0.004369:0.003024:0.009223:0.004385:0.007333:0.003024:0.010175:0.005020
ure 4. :@0.076190:0.881860:0.120701:0.881860:0.120701:0.866077:0.076190:0.866077:0.009192:0.004551:0.009827:0.004188:0.008376:0.004188:0.004188
WHen tO refer:@0.076190:0.914932:0.211825:0.914932:0.211825:0.894767:0.076190:0.894767:0.016631:0.012566:0.009609:0.013674:0.005174:0.007761:0.015522:0.005174:0.010718:0.009609:0.008870:0.009609:0.010718
It is advisable to refer the patient in the following condi-:@0.076190:0.931036:0.480942:0.931036:0.480942:0.915254:0.076190:0.915254:0.003417:0.005125:0.004097:0.003024:0.005866:0.004097:0.010326:0.010357:0.008376:0.003024:0.005866:0.010326:0.010311:0.003024:0.009827:0.004097:0.005125:0.009903:0.004097:0.004551:0.009827:0.004747:0.009827:0.004551:0.004082:0.005125:0.009223:0.009827:0.004082:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.004082:0.003024:0.009223:0.004097:0.005125:0.009223:0.009827:0.004082:0.004747:0.009903:0.003024:0.003024:0.009903:0.012564:0.003024:0.009223:0.010175:0.004082:0.009782:0.009903:0.009223:0.010357:0.003024:0.005020
tions: :@0.076190:0.945364:0.117707:0.945364:0.117707:0.929581:0.076190:0.929581:0.005125:0.003024:0.009903:0.009223:0.005866:0.004188:0.004188
•  When the diagnosis is in doubt :@0.519042:0.084928:0.765074:0.084928:0.765074:0.069145:0.519042:0.069145:0.009162:0.004188:0.006804:0.014514:0.009223:0.009827:0.009223:0.004188:0.005125:0.009223:0.009827:0.004188:0.010357:0.003024:0.010326:0.010175:0.009223:0.009903:0.005866:0.003024:0.005866:0.004188:0.003024:0.005866:0.004188:0.003024:0.009223:0.004188:0.010357:0.009903:0.009192:0.010311:0.005125:0.004188
•  Patients with moderate to severe psoriasis :@0.519042:0.099037:0.847866:0.099037:0.847866:0.083254:0.519042:0.083254:0.009162:0.004188:0.006804:0.008950:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004188:0.012564:0.003024:0.005125:0.009223:0.004188:0.014182:0.009903:0.010357:0.009827:0.004551:0.010326:0.005125:0.009827:0.004188:0.005125:0.009903:0.004188:0.005866:0.009827:0.008376:0.009827:0.004551:0.009827:0.004188:0.010311:0.005866:0.009903:0.004551:0.003024:0.010326:0.005866:0.003024:0.005866:0.004188
•  Erythrodermic psoriasis:@0.519042:0.113145:0.703404:0.113145:0.703404:0.097363:0.519042:0.097363:0.009162:0.004188:0.006804:0.008104:0.004551:0.008104:0.005125:0.009223:0.004551:0.009903:0.010357:0.009827:0.004551:0.014182:0.003024:0.009782:0.004188:0.010311:0.005866:0.009903:0.004551:0.003024:0.010326:0.005866:0.003024:0.005866
•  Pustular psoriasis:@0.519042:0.127254:0.658349:0.127254:0.658349:0.111471:0.519042:0.111471:0.009162:0.004188:0.006804:0.008950:0.009192:0.005866:0.005125:0.009192:0.003024:0.010326:0.004551:0.004188:0.010311:0.005866:0.009903:0.004551:0.003024:0.010326:0.005866:0.003024:0.005866
•  Special  patient  population,  such  as  children,  preg:@0.519042:0.141362:0.918774:0.141362:0.918774:0.125580:0.519042:0.125580:0.009162:0.004188:0.006804:0.007529:0.010311:0.009827:0.009782:0.003024:0.010326:0.003024:0.004188:0.002480:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.004188:0.002464:0.010311:0.009903:0.010311:0.009192:0.003024:0.010326:0.005125:0.003024:0.009903:0.009223:0.004188:0.004188:0.002464:0.005866:0.009192:0.009782:0.009223:0.004188:0.002464:0.010326:0.005866:0.004188:0.002480:0.009782:0.009223:0.003024:0.003024:0.010357:0.004551:0.009827:0.009223:0.004188:0.004188:0.002464:0.010311:0.004551:0.009827:0.010175
-:@0.918774:0.141362:0.923794:0.141362:0.923794:0.125580:0.918774:0.125580:0.005020
nant women, elderly patients with comorbidities, :@0.539196:0.155471:0.927982:0.155471:0.927982:0.139688:0.539196:0.139688:0.009223:0.010326:0.009223:0.005125:0.010054:0.012564:0.009903:0.014182:0.009827:0.009223:0.004188:0.010054:0.009827:0.003024:0.010357:0.009827:0.004551:0.003024:0.008104:0.010054:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.010054:0.012564:0.003024:0.005125:0.009223:0.010054:0.009782:0.009903:0.014182:0.009903:0.004551:0.010311:0.003024:0.010357:0.003024:0.005125:0.003024:0.009827:0.005866:0.004188:0.004188
those with a history of malignancy, and those who :@0.539196:0.169579:0.927967:0.169579:0.927967:0.153797:0.539196:0.153797:0.005125:0.009223:0.009903:0.005866:0.009827:0.006350:0.012564:0.003024:0.005125:0.009223:0.006350:0.010326:0.006365:0.009223:0.003024:0.005866:0.005125:0.009903:0.004551:0.008104:0.006350:0.009903:0.004747:0.006350:0.014182:0.010326:0.003024:0.003024:0.010175:0.009223:0.010326:0.009223:0.009782:0.008104:0.004188:0.006350:0.010326:0.009223:0.010357:0.006350:0.005125:0.009223:0.009903:0.005866:0.009827:0.006350:0.012564:0.009223:0.009903:0.004188
are to have surgical procedures.:@0.539196:0.183688:0.777729:0.183688:0.777729:0.167905:0.539196:0.167905:0.010326:0.004551:0.009827:0.004188:0.005125:0.009903:0.004188:0.009223:0.010326:0.008376:0.009827:0.004188:0.005866:0.009192:0.004551:0.010175:0.003024:0.009782:0.010326:0.003024:0.004188:0.010311:0.004551:0.009903:0.009782:0.009827:0.010357:0.009192:0.004551:0.009827:0.005866:0.004188
•  Psoriatic arthritis:@0.519042:0.197796:0.654751:0.197796:0.654751:0.182014:0.519042:0.182014:0.009162:0.004188:0.006804:0.008950:0.005866:0.009903:0.004551:0.003024:0.010326:0.005125:0.003024:0.009782:0.004188:0.010326:0.004551:0.005125:0.009223:0.004551:0.003024:0.005125:0.003024:0.005866
referenCes:@0.519047:0.230678:0.625485:0.230678:0.625485:0.210514:0.519047:0.210514:0.010718:0.009609:0.008870:0.009609:0.010718:0.009609:0.013674:0.014413:0.009609:0.009609
1. :@0.519047:0.242573:0.532076:0.242573:0.532076:0.230297:0.519047:0.230297:0.006515:0.003257:0.003257
Deng Y, Chang C, Lu Q. The inflammatory response in psoriasis: A :@0.544247:0.242573:0.927070:0.242573:0.927070:0.230297:0.544247:0.230297:0.008749:0.007644:0.007173:0.007914:0.004222:0.006961:0.003257:0.004210:0.009560:0.007173:0.008032:0.007173:0.007914:0.004222:0.009560:0.003257:0.004222:0.005433:0.007150:0.004222:0.010242:0.003257:0.004222:0.005009:0.007173:0.007644:0.004210:0.002352:0.007173:0.002852:0.002852:0.008032:0.011030:0.011030:0.008032:0.003986:0.007702:0.003540:0.006303:0.004210:0.003540:0.007644:0.004563:0.008020:0.007702:0.007173:0.004563:0.007644:0.004210:0.002352:0.007173:0.004222:0.008020:0.004563:0.007702:0.003540:0.002352:0.008032:0.004563:0.002352:0.004563:0.003257:0.004222:0.008702:0.003257
comprehensive review. :@0.544247:0.253474:0.679455:0.253474:0.679455:0.241199:0.544247:0.241199:0.007608:0.007702:0.011030:0.008020:0.003540:0.007644:0.007173:0.007644:0.007173:0.004563:0.002352:0.006515:0.007644:0.002622:0.003540:0.007644:0.006515:0.002352:0.007644:0.009772:0.003257:0.003257
Clin Rev Allergy Immunol.:@0.678832:0.253474:0.820625:0.253474:0.820625:0.241199:0.678832:0.241199:0.009560:0.002352:0.002352:0.007173:0.002634:0.007138:0.007644:0.006515:0.002634:0.008702:0.002352:0.002352:0.007644:0.003540:0.007914:0.006303:0.002634:0.002658:0.011030:0.011030:0.007150:0.007173:0.007702:0.002352:0.003257
 2016;50(3):377-89.:@0.820625:0.253474:0.923789:0.253474:0.923789:0.241199:0.820625:0.241199:0.002634:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.004339:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.003257
2. :@0.519047:0.264376:0.532076:0.264376:0.532076:0.252100:0.519047:0.252100:0.006515:0.003257:0.003257
Rapp sR, :@0.544247:0.264376:0.599821:0.264376:0.599821:0.252100:0.544247:0.252100:0.007138:0.008032:0.008020:0.008020:0.004857:0.005856:0.007138:0.003257:0.003257
et al.:@0.601421:0.264376:0.631536:0.264376:0.631536:0.252100:0.601421:0.252100:0.007644:0.003986:0.004845:0.008032:0.002352:0.003257
 psoriasis causes as much disability as other major :@0.631536:0.264376:0.927070:0.264376:0.927070:0.252100:0.631536:0.252100:0.004857:0.006961:0.004563:0.007702:0.003540:0.002352:0.008032:0.004563:0.002352:0.004563:0.004857:0.007608:0.008032:0.007150:0.004563:0.007644:0.004563:0.004857:0.008032:0.004563:0.004857:0.011030:0.007150:0.007608:0.007173:0.004845:0.008055:0.002352:0.004563:0.008032:0.008020:0.002352:0.002352:0.002352:0.003986:0.006303:0.004868:0.008032:0.004563:0.004857:0.007702:0.003986:0.007173:0.007644:0.003540:0.004845:0.011030:0.008032:0.002387:0.007702:0.003540:0.003257
medical diseases. :@0.544247:0.275277:0.648505:0.275277:0.648505:0.263002:0.544247:0.263002:0.011030:0.007644:0.008055:0.002352:0.007608:0.008032:0.002352:0.003257:0.008055:0.002352:0.004563:0.007644:0.008032:0.004563:0.007644:0.004563:0.003257:0.003257
J Am Acad Dermatol. :@0.648516:0.275277:0.775634:0.275277:0.775634:0.263002:0.648516:0.263002:0.005668:0.003257:0.008702:0.011030:0.003257:0.008702:0.007608:0.008032:0.008055:0.003257:0.008749:0.007644:0.003540:0.011030:0.008032:0.003986:0.007702:0.002352:0.003257:0.003257
1999;41(3 pt 1):401-7.:@0.775622:0.275277:0.893615:0.275277:0.893615:0.263002:0.775622:0.263002:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.004339:0.006515:0.003257:0.006961:0.003986:0.003257:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.003257
3. :@0.519059:0.286179:0.532088:0.286179:0.532088:0.273903:0.519059:0.273903:0.006515:0.003257:0.003257
Kolli ss, :@0.544259:0.286179:0.587839:0.286179:0.587839:0.273903:0.544259:0.273903:0.006950:0.007702:0.002352:0.002352:0.002352:0.003645:0.005856:0.005856:0.003257:0.003257
et al.:@0.588215:0.286179:0.617119:0.286179:0.617119:0.273903:0.588215:0.273903:0.007644:0.003986:0.003634:0.008032:0.002352:0.003257
 psychosocial impact of psoriasis: A review for derma-:@0.617119:0.286179:0.923824:0.286179:0.923824:0.273903:0.617119:0.273903:0.003645:0.006961:0.004563:0.006303:0.007608:0.007173:0.007702:0.004563:0.007702:0.007608:0.002352:0.008032:0.002352:0.003645:0.002352:0.011030:0.008020:0.008032:0.007608:0.003986:0.003634:0.007702:0.003692:0.003634:0.008020:0.004563:0.007702:0.003540:0.002352:0.008032:0.004563:0.002352:0.004563:0.003257:0.003645:0.008702:0.003634:0.003540:0.007644:0.006515:0.002352:0.007644:0.009772:0.003645:0.003692:0.007702:0.003540:0.003634:0.008055:0.007644:0.003540:0.011030:0.008032:0.003904
tology residents. :@0.544259:0.297080:0.639509:0.297080:0.639509:0.284805:0.544259:0.284805:0.003986:0.007702:0.002352:0.007702:0.007914:0.006303:0.003257:0.003540:0.007644:0.004563:0.002352:0.008055:0.007644:0.007173:0.003986:0.004563:0.003257:0.003257
Cutis.:@0.639497:0.297080:0.670365:0.297080:0.670365:0.284805:0.639497:0.284805:0.009560:0.007150:0.003986:0.002352:0.004563:0.003257
 2018;102(5s):21-5.:@0.670365:0.297080:0.773494:0.297080:0.773494:0.284805:0.670365:0.284805:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.004339:0.006515:0.005856:0.004339:0.003257:0.006515:0.006515:0.003904:0.006515:0.003257
4. :@0.519059:0.307982:0.532088:0.307982:0.532088:0.295706:0.519059:0.295706:0.006515:0.003257:0.003257
Liang sE, Cohen JM, Ho Rs. psoriasis and suicidality: A review of the :@0.544259:0.307982:0.927093:0.307982:0.927093:0.295706:0.544259:0.295706:0.005433:0.002352:0.008032:0.007173:0.007914:0.003304:0.005856:0.006303:0.003257:0.003304:0.009560:0.007702:0.007173:0.007644:0.007173:0.003304:0.005668:0.010807:0.003257:0.003304:0.008032:0.007702:0.003304:0.007138:0.005856:0.003257:0.003304:0.006961:0.004563:0.007702:0.003540:0.002352:0.008032:0.004563:0.002352:0.004563:0.003316:0.008032:0.007173:0.008055:0.003304:0.004563:0.007150:0.002352:0.007608:0.002352:0.008055:0.008032:0.002352:0.002352:0.003986:0.006303:0.003257:0.003316:0.008702:0.003304:0.003540:0.007644:0.006515:0.002352:0.007644:0.009772:0.003304:0.007702:0.003692:0.003304:0.003986:0.007173:0.007644:0.003257
literature. :@0.544259:0.318883:0.600997:0.318883:0.600997:0.306608:0.544259:0.306608:0.002352:0.002352:0.003986:0.007644:0.003540:0.008032:0.003986:0.007150:0.003540:0.007644:0.003257:0.003257
Dermatol Ther.:@0.600986:0.318883:0.683900:0.318883:0.683900:0.306608:0.600986:0.306608:0.008749:0.007644:0.003540:0.011030:0.008032:0.003986:0.007702:0.002352:0.003257:0.005009:0.007173:0.007644:0.003540:0.003257
 2018:e12771.:@0.683888:0.318883:0.759935:0.318883:0.759935:0.306608:0.683888:0.306608:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.007644:0.006515:0.006515:0.006515:0.006515:0.006515:0.003257
5. :@0.519059:0.329785:0.532088:0.329785:0.532088:0.317509:0.519059:0.317509:0.006515:0.003257:0.003257
Hawro T, :@0.544259:0.329785:0.597634:0.329785:0.597634:0.317509:0.544259:0.317509:0.008032:0.008032:0.009772:0.003540:0.007702:0.004774:0.005009:0.003257:0.003257
et al. :@0.599151:0.329785:0.632453:0.329785:0.632453:0.317509:0.599151:0.317509:0.007644:0.003986:0.004774:0.008032:0.002352:0.003257:0.003257
Impact of psoriasis severity on family income and :@0.633982:0.329785:0.927070:0.329785:0.927070:0.317509:0.633982:0.317509:0.002658:0.011030:0.008020:0.008032:0.007608:0.003986:0.004786:0.007702:0.003692:0.004774:0.008020:0.004563:0.007702:0.003540:0.002352:0.008032:0.004563:0.002352:0.004563:0.004786:0.004563:0.007644:0.006515:0.007644:0.003540:0.002352:0.003986:0.006303:0.004786:0.007702:0.007173:0.004774:0.003692:0.008032:0.011030:0.002352:0.002352:0.006303:0.004786:0.002352:0.007173:0.007608:0.007702:0.011030:0.007644:0.004774:0.008032:0.007173:0.008055:0.003257
quality of life. J:@0.544259:0.340686:0.628585:0.340686:0.628585:0.328411:0.544259:0.328411:0.008020:0.007150:0.008032:0.002352:0.002352:0.003986:0.006303:0.003257:0.007702:0.003692:0.003257:0.002352:0.002352:0.003692:0.007644:0.003257:0.003257:0.005668
 Eur Acad Dermatol Venereol.:@0.628585:0.340686:0.799247:0.340686:0.799247:0.328411:0.628585:0.328411:0.003257:0.006303:0.007150:0.003540:0.003257:0.008702:0.007608:0.008032:0.008055:0.003257:0.008749:0.007644:0.003540:0.011030:0.008032:0.003986:0.007702:0.002352:0.003257:0.008255:0.007644:0.007173:0.007644:0.003540:0.007644:0.007702:0.002352:0.003257
 2015;29(3):438-43.:@0.799223:0.340686:0.903010:0.340686:0.903010:0.328411:0.799223:0.328411:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.004339:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.003257
6. :@0.519059:0.351587:0.532088:0.351587:0.532088:0.339312:0.519059:0.339312:0.006515:0.003257:0.003257
Boehncke WH, schon Mp. psoriasis. :@0.544259:0.351587:0.745142:0.351587:0.745142:0.339312:0.544259:0.339312:0.006750:0.007702:0.007644:0.007173:0.007173:0.007608:0.005903:0.007644:0.003257:0.011289:0.008032:0.003257:0.003257:0.005856:0.007608:0.007173:0.007702:0.007173:0.003257:0.010807:0.006961:0.003257:0.003257:0.006961:0.004563:0.007702:0.003540:0.002352:0.008032:0.004563:0.002352:0.004563:0.003257:0.003257
Lancet.:@0.745119:0.351587:0.788252:0.351587:0.788252:0.339312:0.745119:0.339312:0.005433:0.008032:0.007173:0.007608:0.007644:0.003986:0.003257
 2015;386(9997):983-94.:@0.788240:0.351587:0.918086:0.351587:0.918086:0.339312:0.788240:0.339312:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.004339:0.006515:0.006515:0.006515:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.003257
7. :@0.519059:0.362489:0.532088:0.362489:0.532088:0.350214:0.519059:0.350214:0.006515:0.003257:0.003257
Hugh JM, Weinberg JM. Update on the pathophysiology of psoria-:@0.544259:0.362489:0.923801:0.362489:0.923801:0.350214:0.544259:0.350214:0.008032:0.007150:0.007914:0.007173:0.003587:0.005668:0.010807:0.003257:0.003587:0.011289:0.007644:0.002352:0.007173:0.008020:0.007644:0.003540:0.007914:0.003587:0.005668:0.010807:0.003257:0.003587:0.007702:0.008020:0.008055:0.008032:0.003986:0.007644:0.003598:0.007702:0.007173:0.003587:0.003986:0.007173:0.007644:0.003587:0.008020:0.008032:0.003986:0.007173:0.007702:0.008020:0.007173:0.006303:0.004563:0.002352:0.007702:0.002352:0.007702:0.007914:0.006303:0.003598:0.007702:0.003692:0.003598:0.008020:0.004563:0.007702:0.003540:0.002352:0.008032:0.003904
sis. :@0.544259:0.373390:0.562251:0.373390:0.562251:0.361115:0.544259:0.361115:0.004563:0.002352:0.004563:0.003257:0.003257
Cutis. :@0.562251:0.373390:0.596376:0.373390:0.596376:0.361115:0.562251:0.361115:0.009560:0.007150:0.003986:0.002352:0.004563:0.003257:0.003257
2018;102(5s):6-12.:@0.596376:0.373390:0.696247:0.373390:0.696247:0.361115:0.596376:0.361115:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.004339:0.006515:0.005856:0.004339:0.003257:0.006515:0.003904:0.006515:0.006515:0.003257
8. :@0.519059:0.384292:0.532088:0.384292:0.532088:0.372017:0.519059:0.372017:0.006515:0.003257:0.003257
Conrad C, Gilliet M. psoriasis: From pathogenesis to targeted thera-:@0.544259:0.384292:0.923824:0.384292:0.923824:0.372017:0.544259:0.372017:0.009560:0.007702:0.007173:0.003540:0.008032:0.008055:0.003104:0.009560:0.003257:0.003104:0.010254:0.002352:0.002352:0.002352:0.002352:0.007644:0.003986:0.003116:0.010807:0.003257:0.003104:0.006961:0.004563:0.007702:0.003540:0.002352:0.008032:0.004563:0.002352:0.004563:0.003257:0.003104:0.005703:0.003540:0.007702:0.011018:0.003104:0.008020:0.008032:0.003986:0.007173:0.007702:0.007914:0.007644:0.007173:0.007644:0.004563:0.002352:0.004563:0.003104:0.003986:0.007702:0.003104:0.003986:0.008032:0.003540:0.007914:0.007644:0.003986:0.007644:0.008055:0.003104:0.003986:0.007173:0.007644:0.003540:0.008032:0.003904
pies. :@0.544259:0.395193:0.573351:0.395193:0.573351:0.382918:0.544259:0.382918:0.008020:0.002352:0.007644:0.004563:0.003257:0.003257
Clin Rev Allergy Immunol.:@0.573351:0.395193:0.717014:0.395193:0.717014:0.382918:0.573351:0.382918:0.009560:0.002352:0.002352:0.007173:0.003257:0.007138:0.007644:0.006515:0.003257:0.008702:0.002352:0.002352:0.007644:0.003540:0.007914:0.006303:0.003257:0.002658:0.011030:0.011030:0.007150:0.007173:0.007702:0.002352:0.003257
 2018;54(1):102-13.:@0.717002:0.395193:0.820790:0.395193:0.820790:0.382918:0.717002:0.382918:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.004339:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.003257
9. :@0.519059:0.406095:0.532088:0.406095:0.532088:0.393819:0.519059:0.393819:0.006515:0.003257:0.003257
Bernhard JD. Clinical  pearl: Auspitz signs  in psoriasis  scale. :@0.544259:0.406095:0.890687:0.406095:0.890687:0.393819:0.544259:0.393819:0.006750:0.007644:0.003540:0.007173:0.007173:0.008032:0.003540:0.008055:0.005492:0.005668:0.008749:0.003257:0.005492:0.009560:0.002352:0.002352:0.007173:0.002352:0.007608:0.008032:0.002352:0.003257:0.002246:0.008020:0.007644:0.008032:0.003540:0.002352:0.003257:0.005492:0.008702:0.007150:0.004563:0.008020:0.002352:0.003986:0.004998:0.005492:0.004563:0.002352:0.007914:0.007173:0.004563:0.003257:0.002246:0.002352:0.007173:0.005492:0.008020:0.004563:0.007702:0.003540:0.002352:0.008032:0.004563:0.002352:0.004563:0.003257:0.002246:0.004563:0.007608:0.008032:0.002352:0.007644:0.003257:0.003257
J Am :@0.892921:0.406095:0.927070:0.406095:0.927070:0.393819:0.892921:0.393819:0.005668:0.005492:0.008702:0.011030:0.003257
Acad Dermatol.:@0.544259:0.416996:0.636205:0.416996:0.636205:0.404721:0.544259:0.404721:0.008702:0.007608:0.008032:0.008055:0.003257:0.008749:0.007644:0.003540:0.011030:0.008032:0.003986:0.007702:0.002352:0.003257
 1997;36(4):621.:@0.636193:0.416996:0.723047:0.416996:0.723047:0.404721:0.636193:0.404721:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.004339:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.003257
10.  Golinska J,  sar-pomian M, Rudnicka L. Dermoscopic features of :@0.519059:0.427898:0.927093:0.427898:0.927093:0.415622:0.519059:0.415622:0.006515:0.006515:0.003257:0.003257:0.005656:0.010254:0.007702:0.002352:0.002352:0.007173:0.004563:0.005903:0.008032:0.005927:0.005668:0.003257:0.003257:0.002669:0.005856:0.008032:0.003540:0.003904:0.006961:0.007702:0.011030:0.002352:0.008032:0.007173:0.005927:0.010807:0.003257:0.005927:0.007138:0.007150:0.008055:0.007173:0.002352:0.007608:0.005903:0.008032:0.005927:0.005433:0.003257:0.005927:0.008749:0.007644:0.003540:0.011030:0.007702:0.004563:0.007608:0.007702:0.008020:0.002352:0.007608:0.005927:0.003692:0.007644:0.008032:0.003986:0.007150:0.003540:0.007644:0.004563:0.005927:0.007702:0.003692:0.003257
psoriasis  of the  skin, scalp and nails – a systematic review. :@0.544259:0.438799:0.893626:0.438799:0.893626:0.426524:0.544259:0.426524:0.008020:0.004563:0.007702:0.003540:0.002352:0.008032:0.004563:0.002352:0.004563:0.003257:0.002152:0.007702:0.003692:0.005397:0.003986:0.007173:0.007644:0.003257:0.002128:0.004563:0.005903:0.002352:0.007173:0.003257:0.005397:0.004563:0.007608:0.008032:0.002352:0.008020:0.005397:0.008032:0.007173:0.008055:0.005397:0.007173:0.008032:0.002352:0.002352:0.004563:0.005397:0.005880:0.005397:0.008032:0.005397:0.004563:0.006303:0.004563:0.003986:0.007644:0.011030:0.008032:0.003986:0.002352:0.007608:0.005397:0.003540:0.007644:0.006515:0.002352:0.007644:0.009772:0.003257:0.003257
J Eur :@0.895767:0.438799:0.927081:0.438799:0.927081:0.426524:0.895767:0.426524:0.005668:0.005397:0.006303:0.007150:0.003540:0.003257
Acad Dermatol Venereol. :@0.544259:0.449701:0.694672:0.449701:0.694672:0.437425:0.544259:0.437425:0.008702:0.007608:0.008032:0.008055:0.003257:0.008749:0.007644:0.003540:0.011030:0.008032:0.003986:0.007702:0.002352:0.003257:0.008255:0.007644:0.007173:0.007644:0.003540:0.007644:0.007702:0.002352:0.003257:0.003257
2018.:@0.694660:0.449701:0.723976:0.449701:0.723976:0.437425:0.694660:0.437425:0.006515:0.006515:0.006515:0.006515:0.003257
11.  Nast  A, :@0.519071:0.460602:0.589979:0.460602:0.589979:0.448327:0.519071:0.448327:0.006515:0.006515:0.003257:0.003257:0.005656:0.008702:0.008032:0.004563:0.003986:0.003257:0.001952:0.008702:0.003257:0.003257
et  al. :@0.591943:0.460602:0.625680:0.460602:0.625680:0.448327:0.591943:0.448327:0.007644:0.003986:0.003257:0.001952:0.008032:0.002352:0.003257:0.003257
European  s3-Guidelines on  the  systemic treatment :@0.627644:0.460602:0.927093:0.460602:0.927093:0.448327:0.627644:0.448327:0.006303:0.007150:0.003540:0.007702:0.008020:0.007644:0.008032:0.007173:0.003257:0.001952:0.005856:0.006515:0.003904:0.010254:0.007150:0.002352:0.008055:0.007644:0.002352:0.002352:0.007173:0.007644:0.004563:0.005221:0.007702:0.007173:0.003257:0.001952:0.003986:0.007173:0.007644:0.003257:0.001952:0.004563:0.006303:0.004563:0.003986:0.007644:0.011030:0.002352:0.007608:0.005221:0.003986:0.003540:0.007644:0.008032:0.003986:0.011030:0.007644:0.007173:0.003986:0.003257
of  psoriasis vulgaris –  Update  2015 –  short  version  –  EDF  in  co-:@0.544271:0.471504:0.923824:0.471504:0.923824:0.459228:0.544271:0.459228:0.007702:0.003692:0.003257:0.003046:0.008020:0.004563:0.007702:0.003540:0.002352:0.008032:0.004563:0.002352:0.004563:0.006315:0.006515:0.007150:0.002352:0.007914:0.008032:0.003540:0.002352:0.004563:0.006315:0.005880:0.003257:0.003046:0.007702:0.008020:0.008055:0.008032:0.003986:0.007644:0.003257:0.003046:0.006515:0.006515:0.006515:0.006515:0.006315:0.005880:0.003257:0.003057:0.005856:0.007173:0.007702:0.003540:0.003986:0.003257:0.003046:0.006515:0.007644:0.003540:0.004563:0.002352:0.007702:0.007173:0.003257:0.003046:0.005880:0.003257:0.003046:0.006303:0.008749:0.005703:0.003257:0.003046:0.002352:0.007173:0.003257:0.003046:0.007608:0.007702:0.003904
operation  with EADV and IpC. :@0.544271:0.482405:0.730949:0.482405:0.730949:0.470130:0.544271:0.470130:0.007702:0.008020:0.007644:0.003540:0.008032:0.003986:0.002352:0.007702:0.007173:0.003257:0.003304:0.009772:0.002352:0.003986:0.007173:0.006573:0.006303:0.008702:0.008749:0.008255:0.006573:0.008032:0.007173:0.008055:0.006573:0.002658:0.006961:0.009560:0.003257:0.003257
J Eur Acad Dermatol Venereol. :@0.734265:0.482405:0.927117:0.482405:0.927117:0.470130:0.734265:0.470130:0.005668:0.006573:0.006303:0.007150:0.003540:0.006573:0.008702:0.007608:0.008032:0.008055:0.006573:0.008749:0.007644:0.003540:0.011030:0.008032:0.003986:0.007702:0.002352:0.006573:0.008255:0.007644:0.007173:0.007644:0.003540:0.007644:0.007702:0.002352:0.003257:0.003257
2015;29(12):2277-94.:@0.544271:0.493307:0.657830:0.493307:0.657830:0.481031:0.544271:0.481031:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.004339:0.006515:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.003257
12.  Lovato  p, :@0.519071:0.504208:0.604067:0.504208:0.604067:0.491933:0.519071:0.491933:0.006515:0.006515:0.003257:0.003257:0.005656:0.005433:0.007702:0.006515:0.008032:0.003986:0.007702:0.003257:0.003692:0.006961:0.003257:0.003257
et  al.:@0.607759:0.504208:0.639979:0.504208:0.639979:0.491933:0.607759:0.491933:0.007644:0.003986:0.003257:0.003692:0.008032:0.002352:0.003257
 Calcipotriol and betamethasone  dipropionate :@0.639979:0.504208:0.927093:0.504208:0.927093:0.491933:0.639979:0.491933:0.006961:0.009560:0.008032:0.002352:0.007608:0.002352:0.008020:0.007702:0.003986:0.003540:0.002352:0.007702:0.002352:0.006961:0.008032:0.007173:0.008055:0.006961:0.008020:0.007644:0.003986:0.008032:0.011030:0.007644:0.003986:0.007173:0.008032:0.004563:0.007702:0.007173:0.007644:0.003257:0.003692:0.008055:0.002352:0.008020:0.003540:0.007702:0.008020:0.002352:0.007702:0.007173:0.008032:0.003986:0.007644:0.003257
exert  additive inhibitory  effects  on  the cytokine  expression of  in-:@0.544271:0.515110:0.923812:0.515110:0.923812:0.502834:0.544271:0.502834:0.007644:0.005644:0.007644:0.003540:0.003986:0.003257:0.002105:0.008032:0.008055:0.008055:0.002352:0.003986:0.002352:0.006515:0.007644:0.005374:0.002352:0.007173:0.007173:0.002352:0.008020:0.002352:0.003986:0.007702:0.003540:0.006303:0.003257:0.002105:0.007644:0.003692:0.003692:0.007644:0.007608:0.003986:0.004563:0.003257:0.002105:0.007702:0.007173:0.003257:0.002105:0.003986:0.007173:0.007644:0.005374:0.007608:0.006303:0.003986:0.007702:0.005903:0.002352:0.007173:0.007644:0.003257:0.002105:0.007644:0.005644:0.008020:0.003540:0.007644:0.004563:0.004563:0.002352:0.007702:0.007173:0.005374:0.007702:0.003692:0.003257:0.002105:0.002352:0.007173:0.003904
flammatory dendritic cell-Th17 cell axis in psoriasis. :@0.544271:0.526011:0.836782:0.526011:0.836782:0.513736:0.544271:0.513736:0.002852:0.002852:0.008032:0.011030:0.011030:0.008032:0.003986:0.007702:0.003540:0.006303:0.004175:0.008055:0.007644:0.007173:0.008055:0.003540:0.002352:0.003986:0.002352:0.007608:0.004175:0.007608:0.007644:0.002352:0.002352:0.003904:0.005009:0.007173:0.006515:0.006515:0.004175:0.007608:0.007644:0.002352:0.002352:0.004175:0.008032:0.005644:0.002352:0.004563:0.004175:0.002352:0.007173:0.004175:0.008020:0.004563:0.007702:0.003540:0.002352:0.008032:0.004563:0.002352:0.004563:0.003257:0.003257
J Dermatol Sci. :@0.837711:0.526011:0.927093:0.526011:0.927093:0.513736:0.837711:0.513736:0.005668:0.004175:0.008749:0.007644:0.003540:0.011030:0.008032:0.003986:0.007702:0.002352:0.004175:0.005856:0.007608:0.002352:0.003257:0.003257
2016;81(3):153-64.:@0.544271:0.536912:0.644801:0.536912:0.644801:0.524637:0.544271:0.524637:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.004339:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.003257
13.  Chen Z. What’s new about the mechanism of methotrexate action :@0.519071:0.547814:0.927070:0.547814:0.927070:0.535539:0.519071:0.535539:0.006515:0.006515:0.003257:0.003257:0.005656:0.009560:0.007173:0.007644:0.007173:0.003199:0.005644:0.003257:0.003199:0.011289:0.007173:0.008032:0.003986:0.004127:0.004563:0.003199:0.007173:0.007644:0.009772:0.003199:0.008032:0.008020:0.007702:0.007150:0.003986:0.003199:0.003986:0.007173:0.007644:0.003199:0.011030:0.007644:0.007608:0.007173:0.008032:0.007173:0.002352:0.004563:0.011030:0.003199:0.007702:0.003692:0.003199:0.011030:0.007644:0.003986:0.007173:0.007702:0.003986:0.003540:0.007644:0.005644:0.008032:0.003986:0.007644:0.003187:0.008032:0.007608:0.003986:0.002352:0.007702:0.007173:0.003257
in psoriasis? :@0.544271:0.558715:0.612945:0.558715:0.612945:0.546440:0.544271:0.546440:0.002352:0.007173:0.003257:0.008020:0.004563:0.007702:0.003540:0.002352:0.008032:0.004563:0.002352:0.004563:0.006950:0.003257
Br J Dermatol. :@0.612945:0.558715:0.694966:0.558715:0.694966:0.546440:0.612945:0.546440:0.006750:0.003540:0.003257:0.005668:0.003257:0.008749:0.007644:0.003540:0.011030:0.008032:0.003986:0.007702:0.002352:0.003257:0.003257
2018;179(4):818-9.:@0.694954:0.558715:0.795484:0.558715:0.795484:0.546440:0.694954:0.546440:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.004339:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.003257
14.  Menting  sp, :@0.519071:0.569617:0.615943:0.569617:0.615943:0.557341:0.519071:0.557341:0.006515:0.006515:0.003257:0.003257:0.005656:0.010807:0.007644:0.007173:0.003986:0.002352:0.007173:0.007914:0.003257:0.002034:0.005856:0.006961:0.003257:0.003257
et al.:@0.617978:0.569617:0.648540:0.569617:0.648540:0.557341:0.617978:0.557341:0.007644:0.003986:0.005292:0.008032:0.002352:0.003257
 Methotrexate  dosing regimen for plaque-type :@0.648540:0.569617:0.927093:0.569617:0.927093:0.557341:0.648540:0.557341:0.005292:0.010807:0.007644:0.003986:0.007173:0.007702:0.003986:0.003540:0.007644:0.005644:0.008032:0.003986:0.007644:0.003257:0.002023:0.008055:0.007702:0.004563:0.002352:0.007173:0.007914:0.005292:0.003540:0.007644:0.007914:0.002352:0.011030:0.007644:0.007173:0.005292:0.003692:0.007702:0.003540:0.005292:0.008020:0.002352:0.008032:0.008020:0.007150:0.007644:0.003904:0.003986:0.006303:0.008020:0.007644:0.003257
psoriasis:  A systematic review of the use of test-dose, start-dose, :@0.544271:0.580518:0.927093:0.580518:0.927093:0.568243:0.544271:0.568243:0.008020:0.004563:0.007702:0.003540:0.002352:0.008032:0.004563:0.002352:0.004563:0.003257:0.003257:0.002187:0.008702:0.005433:0.004563:0.006303:0.004563:0.003986:0.007644:0.011030:0.008032:0.003986:0.002352:0.007608:0.005433:0.003540:0.007644:0.006515:0.002352:0.007644:0.009772:0.005433:0.007702:0.003692:0.005433:0.003986:0.007173:0.007644:0.005433:0.007150:0.004563:0.007644:0.005433:0.007702:0.003692:0.005433:0.003986:0.007644:0.004563:0.003986:0.003904:0.008055:0.007702:0.004563:0.007644:0.003257:0.005433:0.004563:0.003986:0.008032:0.003540:0.003986:0.003904:0.008055:0.007702:0.004563:0.007644:0.003257:0.003257
dosing scheme, dose adjustments, maximum dose and folic acid :@0.544271:0.591420:0.927081:0.591420:0.927081:0.579144:0.544271:0.579144:0.008055:0.007702:0.004563:0.002352:0.007173:0.007914:0.004480:0.004563:0.007608:0.007173:0.007644:0.011030:0.007644:0.003257:0.004480:0.008055:0.007702:0.004563:0.007644:0.004480:0.008032:0.008055:0.002387:0.007150:0.004563:0.003986:0.011030:0.007644:0.007173:0.003986:0.004563:0.003257:0.004480:0.011030:0.008032:0.005644:0.002352:0.011030:0.007150:0.011030:0.004480:0.008055:0.007702:0.004563:0.007644:0.004480:0.008032:0.007173:0.008055:0.004480:0.003692:0.007702:0.002352:0.002352:0.007608:0.004480:0.008032:0.007608:0.002352:0.008055:0.003257
supplementation. :@0.544271:0.602321:0.647611:0.602321:0.647611:0.590046:0.544271:0.590046:0.004563:0.007150:0.008020:0.008020:0.002352:0.007644:0.011030:0.007644:0.007173:0.003986:0.008032:0.003986:0.002352:0.007702:0.007173:0.003257:0.003257
Acta Derm Venereol. :@0.647611:0.602321:0.771883:0.602321:0.771883:0.590046:0.647611:0.590046:0.008702:0.007608:0.003986:0.008032:0.003257:0.008749:0.007644:0.003540:0.011030:0.003257:0.008255:0.007644:0.007173:0.007644:0.003540:0.007644:0.007702:0.002352:0.003257:0.003257
2016;96(1):23-8.:@0.771859:0.602321:0.859360:0.602321:0.859360:0.590046:0.771859:0.590046:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.004339:0.006515:0.004339:0.003257:0.006515:0.006515:0.003904:0.006515:0.003257
15.  Thomaidou E, Ramot Y. Injection site reactions with the use of bio-:@0.519071:0.613223:0.923848:0.613223:0.923848:0.600947:0.519071:0.600947:0.006515:0.006515:0.003257:0.003257:0.005656:0.005009:0.007173:0.007702:0.011030:0.008032:0.002352:0.008055:0.007702:0.007150:0.003904:0.006303:0.003257:0.003916:0.007138:0.008032:0.011030:0.007702:0.003986:0.003916:0.006961:0.003257:0.003916:0.002658:0.007173:0.002387:0.007644:0.007608:0.003986:0.002352:0.007702:0.007173:0.003916:0.004563:0.002352:0.003986:0.007644:0.003916:0.003540:0.007644:0.008032:0.007608:0.003986:0.002352:0.007702:0.007173:0.004563:0.003916:0.009772:0.002352:0.003986:0.007173:0.003916:0.003986:0.007173:0.007644:0.003916:0.007150:0.004563:0.007644:0.003916:0.007702:0.003692:0.003916:0.008020:0.002352:0.007702:0.003904
logical agents. :@0.544271:0.624124:0.631665:0.624124:0.631665:0.611849:0.544271:0.611849:0.002352:0.007702:0.007914:0.002352:0.007608:0.008032:0.002352:0.003257:0.008032:0.007914:0.007644:0.007173:0.003986:0.004563:0.003257:0.003257
Dermatol Ther.:@0.631665:0.624124:0.714580:0.624124:0.714580:0.611849:0.631665:0.611849:0.008749:0.007644:0.003540:0.011030:0.008032:0.003986:0.007702:0.002352:0.003257:0.005009:0.007173:0.007644:0.003540:0.003257
 2019:e12817.:@0.714556:0.624124:0.790604:0.624124:0.790604:0.611849:0.714556:0.611849:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.007644:0.006515:0.006515:0.006515:0.006515:0.006515:0.003257